<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382901</url>
  </required_header>
  <id_info>
    <org_study_id>1VIT05009</org_study_id>
    <nct_id>NCT01382901</nct_id>
  </id_info>
  <brief_title>Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)</brief_title>
  <official_title>A Phase 2a Study Evaluating the Efficacy and Safety of a Novel Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luitpold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luitpold Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the safety of 2 dosage regimens of Intravenous (IV)
      iron Ferric Carboxymaltose (FCM) in comparison to placebo in patients with Restless Legs
      Syndrome (RLS)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Restless Legs Syndrome (IRLS) Total Score</measure>
    <time_frame>Change from Baseline to Day 28</time_frame>
    <description>The scale represents the patients symptoms of RLS. The patient rates his/her symptoms based on 10 questions with a maximum possible score of 40 representing the most severe symptoms while a score of 0 represents no symptoms at all.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Restless Legs Syndrome (RLS)</condition>
  <arm_group>
    <arm_group_label>Intravenous (IV) Iron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Carboxymaltose (FCM)</intervention_name>
    <arm_group_label>Intravenous (IV) Iron</arm_group_label>
    <other_name>VIT-45</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects &gt; or = to 18 years old, and able to give informed consent to
             the study.

          -  RLS signs and symptoms affirming diagnosis. The IRLS Diagnostic Criteria for RLS must
             be met.

          -  Subjects have RLS symptoms &gt; or = to 5 nights per week for at least the past 3 months.

          -  A baseline score &gt; or = to 15 on the IRLS Rating Scale.

          -  At least one leg with an average baseline Periodic Leg Movement while asleep (PLMS) &gt;
             or = to 15 movements per hour and at least 3 days of baseline PLMS data is measurable
             in each leg.

          -  Subjects on anti-depressants, sleep medications, dopamine agonists, benzodiazepines,
             narcotics or other RLS treatments must be off therapy at least one week or 5 half
             lives, whichever is longer before any baseline RLS assessments and PLM measurements
             are obtained.

          -  Subject has regular sleep hours between 9 p.m. and 9 a.m.

          -  Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be
             practicing an acceptable form of birth control.

        Exclusion Criteria:

          -  RLS 2° to other CNS disease or injury. Such disorders include peripheral neuropathy,
             neurodegenerative disorders, and multiple sclerosis.

          -  RLS 2° to Chronic Kidney Disease.

          -  Any pain related or sleep related disorders (e.g. sleep apnea) which may confound the
             outcome measures.

          -  History of neuroleptic akathisia.

          -  Oral iron use (including multivitamins with iron) after screening.

          -  Parenteral iron use within 4 weeks prior to screening.

          -  Parenteral iron use &gt; 125 mg per week within 4 to 8 weeks prior to screening.

          -  History of &gt; or = to 10 blood transfusions in the past 2 years.

          -  Anticipated need for blood transfusion during the study.

          -  Known hypersensitivity reaction to any component to FCM.

          -  Previously participated in an FCM clinical trial.

          -  Chronic or serious active severe infection.

          -  Malignancy (other than basal or squamous cell skin cancer or the subject has been
             cancer free for &gt; 5 years).

          -  Active inflammatory arthritis (e.g. rheumatoid arthritis, SLE).

          -  Receiving prescription medication for the treatment of bronchospasm.

          -  Pregnant or lactating women.

          -  Severe peripheral vascular disease with significant skin changes.

          -  Seizure disorder currently being treated with medication.

          -  Baseline ferritin &gt; 300 ng/mL.

          -  Baseline TSAT &gt; or = to 45%.

          -  History of hemochromatosis or hemosiderosis or other iron storage disorders.

          -  AST or ALT greater than the upper limit of normal.

          -  Hemoglobin greater than the upper limit of normal.

          -  Calcium or phosphorous outside the normal range.

          -  Known positive hepatitis B antigen (HBsAg) or hepatitis C viral antibody (HCV) with
             evidence of active hepatitis.

          -  Known positive HIV-1/HIV-2 antibodies (anti-HIV).

          -  Received an investigational drug within 30 days before randomization.

          -  Chronic alcohol or drug abuse within the past 6 months.

          -  Significant cardiovascular disease, including myocardial infarction within 12 months
             prior to study inclusion, congestive heart failure NYHA (New York Heart Association)
             III or IV, or poorly controlled hypertension according to the judgment of the
             investigator.

          -  Any other pre-existing laboratory abnormality, medical condition or disease which in
             view of the investigator participation in this study may put the subject at risk.

          -  Subject unable to comply with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>May 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>February 23, 2011</results_first_submitted>
  <results_first_submitted_qc>May 31, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2011</results_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study Period: March 23, 2006 to July 16, 2007 Locations: Hospitals and Medical Clinics (15 total sites)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ferric Carboxymaltose (FCM) 2 x 500 mg</title>
          <description>500mg intravenous (IV) dose of FCM on Day 0 and Day 5.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Intravenous (IV) solution of placebo on Day 0 and Day 5.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ferric Carboxymaltose (FCM) 2 x 500 mg</title>
          <description>500mg intravenous (IV) dose of FCM on Day 0 and Day 5.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Intravenous (IV) solution of placebo on Day 0 and Day 5.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.5" spread="11.42"/>
                    <measurement group_id="B2" value="54.1" spread="13.68"/>
                    <measurement group_id="B3" value="51.7" spread="12.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>International Restless Legs Syndrome (IRLS) Total Score</title>
        <description>The scale represents the patients symptoms of RLS. The patient rates his/her symptoms based on 10 questions with a maximum possible score of 40 representing the most severe symptoms while a score of 0 represents no symptoms at all.</description>
        <time_frame>Change from Baseline to Day 28</time_frame>
        <population>Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM) 2 x 500 mg</title>
            <description>500mg intravenous (IV) dose of FCM on Day 0 and Day 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intravenous (IV) solution of placebo on Day 0 and Day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>International Restless Legs Syndrome (IRLS) Total Score</title>
          <description>The scale represents the patients symptoms of RLS. The patient rates his/her symptoms based on 10 questions with a maximum possible score of 40 representing the most severe symptoms while a score of 0 represents no symptoms at all.</description>
          <population>Evaluable Population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="8.52"/>
                    <measurement group_id="O2" value="-4.0" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year and 4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ferric Carboxymaltose (FCM) 2 x 500 mg</title>
          <description>500mg intravenous (IV) dose of FCM on Day 0 and Day 5.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Intravenous (IV) solution of placebo on Day 0 and Day 5.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>undefined</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Falone, MD</name_or_title>
      <organization>Luitpold Pharmaceuticals, Inc.</organization>
      <phone>601-650-4200</phone>
      <email>mfalone@luitpold.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

